Novavax Says U.S. Will Pause Funding for Production of Its Vaccine
#1

Novavax, the Maryland firm that won a $1.75 billion federal contract to develop and produce a coronavirus vaccine, said on Thursday that the federal government would not fund further production of its vaccine until the company resolves concerns of federal regulators about its work.

The firm’s disclosure came in a quarterly filing with the Securities and Exchange Commission. The Trump administration  agreed to buy 110 million doses of vaccine from Novavax as part of its crash vaccine development program.

Although the company reported in June that its vaccine had an efficacy of 90 percent against symptomatic Covid-19 cases, and 100 percent against severe disease, Novavax has struggled for  months to mass manufacture its product. Its vaccine has not been authorized for distribution in the United States, and federal officials said it is unclear when or if it will be.

Four people familiar with Novavax’s operation said the company had been unable so far to demonstrate that its production process met Food and Drug Administration standards. They spoke on the condition of anonymity to discuss sensitive contracting issues.

https://tinyurl.com/3nrny293
Reply
#2

Temasek should invest into it. Why need to succumb to FDA when they themselves have their flaws?
Reply


Forum Jump:


Users browsing this thread: 1 Guest(s)